Potential role of bromelain in clinical and therapeutic applications (Review)

  • Authors:
    • Vidhya Rathnavelu
    • Noorjahan Banu Alitheen
    • Subramaniam Sohila
    • Samikannu Kanagesan
    • Rajendran Ramesh
  • View Affiliations

  • Published online on: July 18, 2016     https://doi.org/10.3892/br.2016.720
  • Pages: 283-288
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pineapple has been used as part of traditional folk medicine since ancient times and it continues to be present in various herbal preparations. Bromelain is a complex mixture of protease extracted from the fruit or stem of the pineapple plant. Although the complete molecular mechanism of action of bromelain has not been completely identified, bromelain gained universal acceptability as a phytotherapeutic agent due to its history of safe use and lack of side effects. Bromelain is widely administered for its well-recognized properties, such as its anti-inflammatory, antithrombotic and fibrinolytic affects, anticancer activity and immunomodulatory effects, in addition to being a wound healing and circulatory improvement agent. The current review describes the promising clinical applications and therapeutic properties of bromelain.

References

1 

Morton J: Pineapple. Fruits of Warm Climates. Julia F. Morton. (Miami, FL). 18–28. 1987.

2 

Scopes RK: Protein Purification: Principles and Practice (2nd). Springer-Verlag. New York, NY: 41–65. 1982.

3 

Arnon R and Shapira E: Antibodies to papain. A selective fractionation according to inhibitory capacity. Biochemistry. 6:3942–3950. 1967. View Article : Google Scholar : PubMed/NCBI

4 

Ota S, Moore S and Stein WH: Preparation and chemical properties of purified stem and fruit bromelains. Biochemistry. 3:180–185. 1964. View Article : Google Scholar : PubMed/NCBI

5 

Murachi T, Yasui M and Yasuda Y: Purification and physical characterization of stem bromelain. Biochemistry. 3:48–55. 1964. View Article : Google Scholar : PubMed/NCBI

6 

Hale LP, Greer PK, Trinh CT and James CL: Proteinase activity and stability of natural bromelain preparations. Int Immunopharmacol. 5:783–793. 2005. View Article : Google Scholar : PubMed/NCBI

7 

Devakate RV, Patil VV, Waje SS and Thorat BN: Purification and drying of bromelain. Separ Purif Tech. 64:259–264. 2009. View Article : Google Scholar

8 

Castell JV, Friedrich G, Kuhn CS and Poppe GE: Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake. Am J Physiol. 273:G139–G146. 1997.PubMed/NCBI

9 

Maurer HR: Bromelain: Biochemistry, pharmacology and medical use. Cell Mol Life Sci. 58:1234–1245. 2001. View Article : Google Scholar : PubMed/NCBI

10 

Mialovyts'ka OA: Effect of phlogenzym in long-term treatment of patients with multiple sclerosis. Lik Sprava. 109–113. 2003.(In Ukrainian).

11 

White RR, Crawley FE, Vellini M and Rovati LA: Bioavailability of 125I bromelain after oral administration to rats. Biopharm Drug Dispos. 9:397–403. 1988. View Article : Google Scholar : PubMed/NCBI

12 

Taussig SJ and Batkin S: Bromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application. An update. J Ethnopharmacol. 22:191–203. 1988. View Article : Google Scholar : PubMed/NCBI

13 

Brien S, Lewith G, Walker A, Hicks SM and Middleton D: Bromelain as a treatment for osteoarthritis: a review of clinical studies. Evid Based Complement Alternat Med. 1:251–257. 2004. View Article : Google Scholar : PubMed/NCBI

14 

Hale LP: Proteolytic activity and immunogenicity of oral bromelain within the gastrointestinal tract of mice. Int Immunopharmacol. 4:255–264. 2004. View Article : Google Scholar : PubMed/NCBI

15 

Sarkar FH and Li Y: Cell signaling pathways altered by natural chemopreventive agents. Mutat Res. 555:53–64. 2004. View Article : Google Scholar : PubMed/NCBI

16 

Huang JR, Wu CC, Hou RC and Jeng KC: Bromelain inhibits lipopolysaccharide-induced cytokine production in human THP-1 monocytes via the removal of CD14. Immunol Invest. 37:263–277. 2008. View Article : Google Scholar : PubMed/NCBI

17 

Bhui K, Prasad S, George J and Shukla Y: Bromelain inhibits COX-2 expression by blocking the activation of MAPK regulated NF-kappa B against skin tumor-initiation triggering mitochondrial death pathway. Cancer Lett. 282:167–176. 2009. View Article : Google Scholar : PubMed/NCBI

18 

Gaspani L, Limiroli E, Ferrario P and Bianchi M: In vivo and in vitro effects of bromelain on PGE(2) and SP concentrations in the inflammatory exudate in rats. Pharmacology. 65:83–86. 2002. View Article : Google Scholar : PubMed/NCBI

19 

Desser L, Rehberger A and Paukovits W: Proteolytic enzymes and amylase induce cytokine production in human peripheral blood mononuclear cells in vitro. Cancer Biother. 9:253–263. 1994. View Article : Google Scholar : PubMed/NCBI

20 

Engwerda CR, Andrew D, Murphy M and Mynott TL: Bromelain activates murine macrophages and natural killer cells in vitro. Cell Immunol. 210:5–10. 2001. View Article : Google Scholar : PubMed/NCBI

21 

Engwerda CR, Andrew D, Ladhams A and Mynott TL: Bromelain modulates T cell and B cell immune responses in vitro and in vivo. Cell Immunol. 210:66–75. 2001. View Article : Google Scholar : PubMed/NCBI

22 

Barth H, Guseo A and Klein R: In vitro study on the immunological effect of bromelain and trypsin on mononuclear cells from humans. Eur J Med Res. 10:325–331. 2005.PubMed/NCBI

23 

Onken JE, Greer PK, Calingaert B and Hale LP: Bromelain treatment decreases secretion of pro-inflammatory cytokines and chemokines by colon biopsies in vitro. Clin Immunol. 126:345–352. 2008. View Article : Google Scholar : PubMed/NCBI

24 

Hale LP, Greer PK, Trinh CT and Gottfried MR: Treatment with oral bromelain decreases colonic inflammation in the IL-10-deficient murine model of inflammatory bowel disease. Clin Immunol. 116:135–142. 2005. View Article : Google Scholar : PubMed/NCBI

25 

Stopper H, Schinzel R, Sebekova K and Heidland A: Genotoxicity of advanced glycation end products in mammalian cells. Cancer Lett. 190:151–156. 2003. View Article : Google Scholar : PubMed/NCBI

26 

Makrydimas G, Zagorianakou N, Zagorianakou P and Agnantis NJ: CD44 family and gynaecological cancer. In Vivo. 17:633–640. 2003.PubMed/NCBI

27 

Subramaniam V, Gardner H and Jothy S: Soluble CD44 secretion contributes to the acquisition of aggressive tumor phenotype in human colon cancer cells. Exp Mol Pathol. 83:341–346. 2007. View Article : Google Scholar : PubMed/NCBI

28 

Massagué J: TGFbeta in Cancer. Cell. 134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI

29 

Bierie B and Moses HL: Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 6:506–520. 2006. View Article : Google Scholar : PubMed/NCBI

30 

Leipner J, Iten F and Saller R: Therapy with proteolytic enzymes in rheumatic disorders. BioDrugs. 15:779–789. 2001. View Article : Google Scholar : PubMed/NCBI

31 

Vellini M, Desideri D, Milanese A, Omini C, Daffonchio L, Hernandez A and Brunelli G: Possible involvement of eicosanoids in the pharmacological action of bromelain. Arzneimittelforschung. 36:110–112. 1986.PubMed/NCBI

32 

Inoue K, Motonaga A, Dainaka J, Nishimura T, Hashii H, Yamate K, Ueda F and Kimura K: Effect of etodolac on prostaglandin E2 biosynthesis, active oxygen generation and bradykinin formation. Prostaglandins Leukot Essent Fatty Acids. 51:457–462. 1994. View Article : Google Scholar : PubMed/NCBI

33 

Oh-ishi S, Uchida Y, Ueno A and Katori M: Bromelian, a thiolprotease from pineapple stem, depletes high molecular weight kininogen by activation of Hageman factor (Factor XIII). Thromb Res. 14:665–672. 1979. View Article : Google Scholar : PubMed/NCBI

34 

Seligman B: Bromelain: An anti-inflammatory agent. Angiology. 13:508–510. 1962. View Article : Google Scholar : PubMed/NCBI

35 

Giacca S: Clinical experiences on the action of bromelin in peripheral venous diseases and in chronic bronchitic states. Minerva Med. 56:1041965.(In Italian).

36 

Moss JN, Frazier CV and Martin GJ: Bromelains. The pharmacology of the enzymes. Arch Int Pharmacodyn Ther. 145:166–189. 1963.PubMed/NCBI

37 

De-Giuli M and Pirotta F: Bromelain, interaction with some protease inhibitor and rabbit specific antiserum. Drugs Exp Clin Res. 4:21–23. 1978.

38 

Chobotova K, Vernallis AB and Majid FA: Bromelain's activity and potential as an anti-cancer agent: current evidence and perspectives. Cancer Lett. 290:148–156. 2010. View Article : Google Scholar : PubMed/NCBI

39 

Beuth J and Braun JM: Modulation of murine tumor growth and colonization by bromelaine, an extract of the pineapple plant (Ananas comosum L.). In Vivo. 19:483–485. 2005.PubMed/NCBI

40 

Báez R, Lopes MT, Salas CE and Hernández M: In vivo antitumoral activity of stem pineapple (Ananas comosus) bromelain. Planta Med. 73:1377–1383. 2007. View Article : Google Scholar : PubMed/NCBI

41 

Zavadova E, Desser L and Mohr T: Stimulation of reactive oxygen species production and cytotoxicity in human neutrophils in vitro and after oral administration of a polyenzyme preparation. Cancer Biother. 10:147–152. 1995. View Article : Google Scholar : PubMed/NCBI

42 

Eckert K, Grabowska E, Stange R, Schneider U, Eschmann K and Maurer HR: Effects of oral bromelain administration on the impaired immunocytotoxicity of mononuclear cells from mammary tumor patients. Oncol Rep. 6:1191–1199. 1999.PubMed/NCBI

43 

Snowden HM, Renfrew MJ and Woolridge MW: Treatments for breast engorgement during lactation. Cochrane Database Syst Rev. 2:CD0000462001.PubMed/NCBI

44 

Guimarães-Ferreira CA, Rodrigues EG, Mortara RA, Cabral H, Serrano FA, Ribeiro-dos-Santos R and Travassos LR: Antitumor effects in vitro and in vivo and mechanisms of protection against melanoma B16F10-Nex2 cells by fastuosain, a cysteine proteinase from Bromelia fastuosa. Neoplasia. 9:723–733. 2007. View Article : Google Scholar : PubMed/NCBI

45 

Tysnes BB, Maurer HR, Porwol T, Probst B, Bjerkvig R and Hoover F: Bromelain reversibly inhibits invasive properties of glioma cells. Neoplasia. 3:469–479. 2001. View Article : Google Scholar : PubMed/NCBI

46 

Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008. View Article : Google Scholar : PubMed/NCBI

47 

Juhasz B, Thirunavukkarasu M, Pant R, Zhan L, Penumathsa SV, Secor ER Jr, Srivastava S, Raychaudhuri U, Menon VP, Otani H, et al: Bromelain induces cardioprotection against ischemia-reperfusion injury through Akt/FOXO pathway in rat myocardium. Am J Physiol Heart Circ Physiol. 294:H1365–H1370. 2008. View Article : Google Scholar : PubMed/NCBI

48 

Ferris RL and Grandis JR: NF-kappaB gene signatures and p53 mutations in head and neck squamous cell carcinoma. Clin Cancer Res. 13:5663–5664. 2007. View Article : Google Scholar : PubMed/NCBI

49 

Chen F, Beezhold K and Castranova V: Tumor promoting or tumor suppressing of NF-kappa B, a matter of cell context dependency. Int Rev Immunol. 27:183–204. 2008. View Article : Google Scholar : PubMed/NCBI

50 

Hou RC, Chen YS, Huang JR and Jeng KC: Cross-linked bromelain inhibits lipopolysaccharide-induced cytokine production involving cellular signaling suppression in rats. J Agric Food Chem. 54:2193–2198. 2006. View Article : Google Scholar : PubMed/NCBI

51 

Taussig SJ, Szekerczes J and Batkin S: Inhibition of tumour growth in vitro by bromelain, an extract of the pineapple plant (Ananas comosus). Planta Med. 51:538–539. 1985. View Article : Google Scholar : PubMed/NCBI

52 

Kleef R, Delohery TM and Bovbjerg DH: Selective modulation of cell adhesion molecules on lymphocytes by bromelain protease 5. Pathobiology. 64:339–346. 1996. View Article : Google Scholar : PubMed/NCBI

53 

Gerard G: Anti-cancer therapy with bromelain. Agress. 3:261–274. 1972.

54 

Nieper HA: A program for the treatment of cancer. Krebs. 6:124–127. 1974.

55 

Philchenkov A: Caspases: potential targets for regulating cell death. J Cell Mol Med. 8:432–444. 2004. View Article : Google Scholar : PubMed/NCBI

56 

Li Q, Withoff S and Verma IM: Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends Immunol. 26:318–325. 2005. View Article : Google Scholar : PubMed/NCBI

57 

Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 435:677–681. 2005. View Article : Google Scholar : PubMed/NCBI

58 

Netti C, Bandi GL and Pecile A: Anti-inflammatory action of proteolytic enzymes of animal vegetable or bacterial origin administered orally compared with that of known anti-phlogistic compounds. Farmaco Prat. 8:453–466. 1972.

59 

Smyth RD, Brennan R and Martin GJ: Systemic biochemical changes following the oral administration of a proteolytic enzyme, bromelain. Arch Int Pharmacodyn Ther. 136:230–236. 1962.PubMed/NCBI

60 

Garbin F, Harrach T, Eckert K and Maurer HR: Bromelain proteinase-f9 augments human lymphocyte-mediated growth-inhibition of various tumor cells in vitro. Int J Oncol. 5:197–203. 1994.PubMed/NCBI

61 

Gläser D and Hilberg T: The influence of bromelain on platelet count and platelet activity in vitro. Platelets. 17:37–41. 2006. View Article : Google Scholar : PubMed/NCBI

62 

Kalra N, Bhui K, Roy P, Srivastava S, George J, Prasad S and Shukla Y: Regulation of p53, nuclear factor kappaB and cyclooxygenase-2 expression by bromelain through targeting mitogen-activated protein kinase pathway in mouse skin. Toxicol Appl Pharmacol. 226:30–37. 2008. View Article : Google Scholar : PubMed/NCBI

63 

Kim JK, Kim Y, Na KM, Surh YJ and Kim TY: [6]-Gingerol prevents UVB-induced ROS production and COX-2 expression in vitro and in vivo. Free Radic Res. 41:603–614. 2007. View Article : Google Scholar : PubMed/NCBI

64 

Karlsen M, Hovden AO, Vogelsang P, Tysnes BB and Appel S: Bromelain treatment leads to maturation of monocyte-derived dendritic cells but cannot replace PGE2 in a cocktail of IL-1β, IL-6, TNF-α and PGE2. Scand J Immunol. 74:135–143. 2011. View Article : Google Scholar : PubMed/NCBI

65 

Wu SY, Hu W, Zhang B, Liu S, Wang JM and Wang AM: Bromelain ameliorates the wound microenvironment and improves the healing of firearm wounds. J Surg Res. 176:503–509. 2012. View Article : Google Scholar : PubMed/NCBI

66 

Wallace JM: Nutritional and botanical modulation of the inflammatory cascade - eicosanoids, cyclooxygenases, and lipoxygenases - as an adjunct in cancer therapy. Integr Cancer Ther. 1:7–37. 2002. View Article : Google Scholar : PubMed/NCBI

67 

Manosroi A, Chankhampan C, Manosroi W and Manosroi J: Toxicity reduction and MMP-2 stimulation of papain and bromelain loaded in elastic niosomes. J Biomed Nanotechnol. 8:720–729. 2012. View Article : Google Scholar : PubMed/NCBI

68 

Mynott TL, Guandalini S, Raimondi F and Fasano A: Bromelain prevents secretion caused by Vibrio cholerae and Escherichia coli enterotoxins in rabbit ileum in vitro. Gastroenterology. 113:175–184. 1997. View Article : Google Scholar : PubMed/NCBI

69 

Chandler DS and Mynott TL: Bromelain protects piglets from diarrhoea caused by oral challenge with K88 positive enterotoxigenic Escherichia coli. Gut. 43:196–202. 1998. View Article : Google Scholar : PubMed/NCBI

70 

Mynott TL, Luke RK and Chandler DS: Oral administration of protease inhibits enterotoxigenic Escherichia coli receptor activity in piglet small intestine. Gut. 38:28–32. 1996. View Article : Google Scholar : PubMed/NCBI

71 

Stepek G, Lowe AE, Buttle DJ, Duce IR and Behnke JM: In vitro and in vivo anthelmintic efficacy of plant cysteine proteinases against the rodent gastrointestinal nematode, Trichuris muris. Parasitology. 132:681–689. 2006. View Article : Google Scholar : PubMed/NCBI

72 

Stepek G, Buttle DJ, Duce IR, Lowe A and Behnke JM: Assessment of the anthelmintic effect of natural plant cysteine proteinases against the gastrointestinal nematode, Heligmosomoides polygyrus, in vitro. Parasitology. 130:203–211. 2005. View Article : Google Scholar : PubMed/NCBI

73 

Brakebusch M, Wintergerst U, Petropoulou T, Notheis G, Husfeld L, Belohradsky BH and Adam D: Bromelain is an accelerator of phagocytosis, respiratory burst and Killing of Candida albicans by human granulocytes and monocytes. Eur J Med Res. 6:193–200. 2001.PubMed/NCBI

74 

Massimiliano R, Pietro R, Paolo S, Sara P and Michele F: Role of bromelain in the treatment of patients with pityriasis lichenoides chronica. J Dermatolog Treat. 18:219–222. 2007. View Article : Google Scholar : PubMed/NCBI

75 

Tinozzi S and Venegoni A: Effect of bromelain on serum and tissue levels of amoxicillin. Drugs Exp Clin Res. 4:39–44. 1978.

76 

Luerti M and Vignali ML: Influence of bromelain on penetration of antibiotics in uterus, salpinx and ovary. Drugs Exp Clin Res. 4:45–48. 1978.

77 

Shahid SK, Turakhia NH, Kundra M, Shanbag P, Daftary GV and Schiess W: Efficacy and safety of phlogenzym - a protease formulation, in sepsis in children. J Assoc Physicians India. 50:527–531. 2002.PubMed/NCBI

78 

Neubauer RA: A plant protease for potentiation of and possible replacement of antibiotics. Exp Med Surg. 19:143–160. 1961.PubMed/NCBI

79 

Ryan RE: A double-blind clinical evaluation of bromelains in the treatment of acute sinusitis. Headache. 7:13–17. 1967. View Article : Google Scholar : PubMed/NCBI

80 

Mori S, Ojima Y, Hirose T, Sasaki T and Hashimoto Y: The clinical effect of proteolytic enzyme containing bromelain and trypsin on urinary tract infection evaluated by double blind method. Acta Obstet Gynaecol Jpn. 19:147–153. 1972.PubMed/NCBI

81 

Glade MJ, Kendra D and Kaminski MV Jr: Improvement in protein utilization in nursing-home patients on tube feeding supplemented with an enzyme product derived from Aspergillus niger and bromelain. Nutrition. 17:348–350. 2001. View Article : Google Scholar : PubMed/NCBI

82 

Knill-Jones RP, Pearce H, Batten J and Williams R: Comparative trial of Nutrizym in chronic pancreatic insufficiency. BMJ. 4:21–24. 1970. View Article : Google Scholar : PubMed/NCBI

83 

Balakrishnan V, Hareendran A and Nair CS: Double-blind cross-over trial of an enzyme preparation in pancreatic steatorrhoea. J Assoc Physicians India. 29:207–209. 1981.PubMed/NCBI

84 

Pellicano R, Strona S, Simondi D, Reggiani S, Pallavicino F, Sguazzini C, Bonagura AG, Rizzetto M and Astegiano M: Benefit of dietary integrators for treating functional dyspepsia: a prospective pilot study. Minerva Gastroenterol Dietol. 55:227–235. 2009.PubMed/NCBI

85 

Blonstein JL: Control of swelling in boxing injuries. Practitioner. 185:781960.PubMed/NCBI

86 

Uhlig G and Seifert J: The effect of proteolytic enzymes (traumanase) on posttraumatic edema. Fortschr Med. 99:554–556. 1981.(In German). PubMed/NCBI

87 

Nieper HA: Effect of bromelain on coronary heart disease and angina pectoris. Acta Med Empirica. 5:274–278. 1978.

88 

Nieper HA: Decrease of the incidence of coronary heart infarct by Mg- and K-orotate and bromelain. Acta Med Empirica. 12:614–618. 1977.

89 

Seligman B: Oral bromelains as adjuncts in the treatment of acute thrombophlebitis. Angiology. 20:22–26. 1969. View Article : Google Scholar : PubMed/NCBI

90 

Gutfreund AE, Taussig SJ and Morris AK: Effect of oral bromelain on blood pressure and heart rate of hypertensive patients. Hawaii Med J. 37:143–146. 1978.PubMed/NCBI

91 

Gailhofer G, Wilders-Truschnig M, Smolle J and Ludvan M: Asthma caused by bromelain: an occupational allergy. Clin Allergy. 18:445–450. 1988. View Article : Google Scholar : PubMed/NCBI

92 

Bahde R, Palmes D, Minin E, Stratmann U, Diller R, Haier J and Spiegel HU: Bromelain ameliorates hepatic microcirculation after warm ischemia. J Surg Res. 139:88–96. 2007. View Article : Google Scholar : PubMed/NCBI

93 

Bloomer RJ: The role of nutritional supplements in the prevention and treatment of resistance exercise-induced skeletal muscle injury. Sports Med. 37:519–532. 2007. View Article : Google Scholar : PubMed/NCBI

94 

Felton GE: Fibrinolytic and antithrombotic action of bromelain may eliminate thrombosis in heart patients. Med Hypotheses. 6:1123–1133. 1980. View Article : Google Scholar : PubMed/NCBI

95 

Lotz-Winter H: On the pharmacology of bromelain: an update with special regard to animal studies on dose-dependent effects. Planta Med. 56:249–253. 1990. View Article : Google Scholar : PubMed/NCBI

96 

Shibayama Y: An experimental study into the cause of acute haemorrhagic gastritis in cirrhosis. J Pathol. 149:307–313. 1986. View Article : Google Scholar : PubMed/NCBI

97 

Kane S and Goldberg MJ: Use of bromelain for mild ulcerative colitis. Ann Intern Med. 132:6802000. View Article : Google Scholar : PubMed/NCBI

98 

Walker AF, Bundy R, Hicks SM and Middleton RW: Bromelain reduces mild acute knee pain and improves well-being in a dose-dependent fashion in an open study of otherwise healthy adults. Phytomedicine. 9:681–686. 2002. View Article : Google Scholar : PubMed/NCBI

99 

Secor ER, Carson WF, Singh A, Pensa M, Guernsey LA, Schramm CM and Thrall RS: Oral bromelain attenuates inflammation in an ovalbumin-induced murine model of asthma. Evid Based Complement Alternat Med. 5:61–69. 2008. View Article : Google Scholar : PubMed/NCBI

100 

Secor ER Jr, Carson WF IV, Cloutier MM, Guernsey LA, Schramm CM, Wu CA and Thrall RS: Bromelain exerts anti-inflammatory effects in an ovalbumin-induced murine model of allergic airway disease. Cell Immunol. 237:68–75. 2005. View Article : Google Scholar : PubMed/NCBI

101 

Seltzer AP: Adjunctive use of bromelains in sinusitis: a controlled study. Eye Ear Nose Throat Mon. 46:1281–1288. 1967.PubMed/NCBI

102 

Braun JM, Schneider B and Beuth HJ: Therapeutic use, efficiency and safety of the proteolytic pineapple enzyme Bromelain-POS in children with acute sinusitis in Germany. In Vivo. 19:417–421. 2005.PubMed/NCBI

103 

Zatuchni GI and Colombi DJ: Bromelains therapy for the prevention of episiotomy pain. Obstet Gynecol. 29:275–278. 1967.PubMed/NCBI

104 

Ahle NW and Hamlet MP: Enzymatic frostbite eschar debridement by bromelain. Ann Emerg Med. 16:1063–1065. 1987. View Article : Google Scholar : PubMed/NCBI

105 

Rovenská E, Svík K, Stancíková M and Rovenský J: Enzyme and combination therapy with cyclosporin A in the rat developing adjuvant arthritis. Int J Tissue React. 21:105–111. 1999.PubMed/NCBI

106 

Cohen A and Goldman J: Bromelain's therapy in rheumatoid arthritis. Pa Med J. 67:27–30. 1964.PubMed/NCBI

107 

Grover AK and Samson SE: Benefits of antioxidant supplements for knee osteoarthritis: rationale and reality. Nutr J. 15:12016. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2016
Volume 5 Issue 3

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Rathnavelu, V., Alitheen, N.B., Sohila, S., Kanagesan, S., & Ramesh, R. (2016). Potential role of bromelain in clinical and therapeutic applications (Review). Biomedical Reports, 5, 283-288. https://doi.org/10.3892/br.2016.720
MLA
Rathnavelu, V., Alitheen, N. B., Sohila, S., Kanagesan, S., Ramesh, R."Potential role of bromelain in clinical and therapeutic applications (Review)". Biomedical Reports 5.3 (2016): 283-288.
Chicago
Rathnavelu, V., Alitheen, N. B., Sohila, S., Kanagesan, S., Ramesh, R."Potential role of bromelain in clinical and therapeutic applications (Review)". Biomedical Reports 5, no. 3 (2016): 283-288. https://doi.org/10.3892/br.2016.720